Figure 3
From: Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer
NV1066 treats TNBC xenografts efficiently and downregulates activation of MAPK signaling in vivo. (a) Flank tumors with MDA-MB-231 were treated with 100 μl of PBS (control) or 1 × 107 PFU of NV1066. Arrow indicates time of viral treatment (day 0). Data represent means±s.e.m. with n⩾6 per group. *P<0.05. (b) Representative images of p-MAPK immunostaining for cryo-frozen tumor tissues in MDA-MB-231 tumors. Images represent IHC staining of tumors after 2 weeks of treatment compared with controls. Treated sections demonstrate less staining for p-MAPK compared with control tumors.
